Fundamental Analysis of Candel Therapeutics Inc - Growth / Value Index


CADL - Valuation Highlights

Valuation Analysis

   Tsr Value Index - Very Poor Score of 5.00
   Price to Book Ratio of 2520.82 suggesting that it is very expensive
   Book Value in last 3 years is trending down
Valuation Key Ratios
Ratio TTM Latest FY Yoy Change MRQ
Price to Earning -2231.90 -10422.40 -58993.88 %
Price to Book 3717.38 26108.73 375726 % 56.16
Price to Sales 46956.57 10734058 404689 %
Enterprise Value to EBITDA Multiple -8.91 -10735.35 -66447.73 %


CADL - Profitability Highlights

Profitability Analysis

   Tsr Profitability Index - Very Poor Score of 5.00
   Piotroski F Score - Very Poor Value of 0.0
   Very Low Dividend Yield of 0 %
   Negative Net profit for last two years
   Company Net profit is Negative for last 5 Quarters
   In the last three years, the company has given poor Returns on Equity
   In the last three years, the company has given poor Returns on Assets
   EPS decline for last four quarters
   Negative Net Margin MRQ
Profitability Key Ratios
Ratio TTM Latest FY Yoy Change MRQ
Return On Equity -166.56 -250.51 -535.98 % -137.50
Return On Asset -75.05 -77.49 -220.33 % -26.34
Net Profit Margin -2103.89 -102990.32 -584.99 % 0
Operating Profit Margin -2064.19 -116419.35 -319.11 % 0
EBITDA Margin -2046.62 -99983.87 -613.11 % 0


Highlights
Market Cap337496 K
Enterprise Value323872 K
Price/Book TTM3717.38
Outstanding Share29347.50 K
Float/ Outstanding Share62.08%
Dividend Yield0 %
Share Holding
Guru Numbers
Price/Graham No0
Peter Lynch Ratio0
Piotroski F Score0
Altman Z Score0.541
Sloan Ratio0.0432
Peter Lynch Fair Value0


CADL - Growth Highlights

Growth Analysis

   YoY Net Margin Jump by 584.99%
   Quarterly sales in last 5 years is trending up
   Tsr Growth Index - Very Poor Score of 10.09
   Annual sales in last 3 years is trending down
   Companies' sales dropped by 75.20 % from last year
   Operating Cash Flow decreasing for last 3 year
Growth Key Fields
Field TTM YoY Growth QoQ Growth
Revenue 1776.00 K 75.20 % 100.00 %
Gross Profit -1164.00 K 1060.00 % 19.55 %
EBITDA -36348.00 K 76.85 % 21.03 %
Net Profit -37365.00 K 69.88 % 25.90 %
EPS -0.0052 99.83 % NA


CADL - Stability Highlights

Stability Analysis

   Tsr Stability Index - Very Poor Score of 9.38
   Altman Z Score of 0.0457 suggest high risk
   Company has high debt burden
   Company is unable to generate enough free cash to support the business.
   Interest Coverage of -12.30
Stability Key Ratios
Ratio Latest FY Yoy Change MRQ
Debt to Equity Ratio 1.71 282.72 % 1.72
Cash Ratio 2.50 -79.99 %
Quick Ratio 0 0 % 2.00
Shareholders Equity 30.93 -49.63 %
Debt to EBITDA -0.703 42.20 %


Historical Valuation Ratios of Candel Therapeutics Inc

Historical Valuation Ratios
Loading ...

Historical Profitability Ratios of Candel Therapeutics Inc

Historical Profitability Ratios
Loading ...

Historical Efficiency Ratios of Candel Therapeutics Inc

Historical Efficiency Ratios
Loading ...

Historical Solvency Ratios of Candel Therapeutics Inc

Historical Solvency Ratios
Loading ...


Note : All Data Generated at the End of Trading Hours (EOD Data)